Home » Healthcare » Pharmaceuticals » Narcolepsy Drugs Market

Narcolepsy Drugs Market By Drug Class (Stimulants, Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs), Tricyclic Antidepressants (TCAs), Histamine H3 Receptor Antagonists) By Symptom Management (Excessive Daytime Sleepiness (EDS), Cataplexy, Sleep Paralysis and Hallucinations, Overall Symptom Management)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Market Insights

The global demand for narcolepsy drugs was valued at USD 2748.5 Million in 2022 and is expected to reach USD 5848.9 Million in 2030, growing at a CAGR of 9.9% between 2023 and 2030.
The stimulants segment is the market leader by drug class, accounting for more than 30% of total value in 2022, while the tricyclic antidepressants (TCAs) segment is estimated to grow rapidly over the projection period.
The clinics end-user category is expected to expand quickly in the anticipated period, while the hospitals segment has the largest market share in 2022.
The excessive daytime sleepiness (EDS) segment dominates the global need for narcolepsy drugs, accounting for more than 35% in 2022 and is predicted to expand at a high CAGR.
The adult category dominated the global market with 65% of the total revenue share by age group.
North America is driving the expansion of the narcolepsy drugs business, accounting for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe had a market revenue share of more than 20%.
Narcolepsy is a long-term sleep disease that leads to sudden, uncontrollable sleep episodes that disrupt every aspect of a patient’s life, causing difficulties in everyday activities.
The rising global prevalence of narcolepsy disease, increased R&D activities and investments, and the development of novel drugs are some of the primary factors propelling the narcolepsy drugs market expansion.
Narcolepsy affects over 3 million people globally and about 200,000 people in the United States, as per the estimates from the National Institute of Neurological Disorders & Stroke (NINDS).

Executive Summary

Market Definition

The narcolepsy drugs market encompasses pharmaceuticals and medications specifically designed and prescribed for the treatment of narcolepsy, a neurological sleep disorder characterized by sudden loss of muscle tone, excessive daytime sleepiness, hallucinations, and disrupted nighttime sleep patterns. These drugs aim to alleviate narcolepsy symptoms, improve wakefulness, and enhance the overall quality of life for individuals living with this chronic condition. Narcolepsy drugs include various categories, such as stimulants, wake-promoting agents, antidepressants, and other medications, often used in combination to manage the diverse range of symptoms associated with narcolepsy.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global narcolepsy drugs market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 9.9% between 2023 and 2030. The market was valued at USD 2748.5 million in 2022 and is expected to reach USD 5848.9 million in 2030.

Narcolepsy is a persistent sleep disorder in which the brain’s capacity to govern sleep-wake cycles is impaired. It is characterized by extreme daytime sleepiness and unexpected sleep attacks. People who have narcolepsy frequently struggle to stay alert for extended periods and experience excessive sleepiness for most of the day.

Many people who have narcolepsy have irregular and interrupted sleep, which might include waking up repeatedly during the night. Narcolepsy might interfere with a person’s regular activities. People suffering from narcolepsy may unintentionally fall asleep while eating, driving, or talking. It is frequently the first symptom to occur and is often the most bothersome, making it difficult to concentrate on specific activities. Other symptoms include abrupt muscle weakness when awake, which causes a person to become limp or unable to move (cataplexy). Narcolepsy is a lifelong condition that cannot be totally cured, but symptoms can be improved over time with the right drugs and lifestyle modifications.

Increased stress among individuals leads to a stressful lifestyle, and an upsurge in intake of alcohol, tobacco, and other dangerous, addictive substances is likely to raise the risk of narcolepsy. Drug development for the treatment of narcolepsy has accelerated in recent years. Furthermore, governments in countries such as India, China, and South Africa are pushing the manufacturing of narcolepsy drugs due to their health benefits, which is projected to enhance the narcolepsy drugs market growth throughout the forecast time frame.

Segmentation by Drug Class

The tricyclic antidepressants (TCAs) segment is anticipated to demonstrate the highest CAGR in the forecast period. TCAs, such as imipramine and clomipramine, are sometimes prescribed off-label for narcolepsy due to their potential to reduce cataplexy and improve nighttime sleep quality. The increasing focus on repurposing existing drugs for narcolepsy treatment is driving the growth of this segment.
Stimulants currently dominate the global narcolepsy drugs market, comprising over 30% of the market share in 2022. This class of drugs includes amphetamines and methylphenidate-based medications like modafinil and armodafinil. Stimulants are widely prescribed to manage EDS in narcolepsy patients, providing alertness and wakefulness during the day.

Segmentation by Symptom Management

The cataplexy segment is projected to register the highest CAGR. Cataplexy, characterized by sudden muscle weakness or paralysis triggered by emotions, is a hallmark symptom of narcolepsy. Innovative treatment options targeting cataplexy are being developed to address this challenging symptom, fueling the segment’s growth.
The excessive daytime sleepiness (EDS) segment leads the market, with a share of over 35% in 2022. EDS is the most common and debilitating symptom of narcolepsy, leading to a reduced quality of life. The demand for drugs that effectively manage EDS remains high, prompting ongoing research into improved treatment options.

Segmentation by End User

Hospitals constitute the dominant category, accounting for more than 40% of the global narcolepsy drugs market demand in 2022. This is primarily due to the need for specialized diagnostic services, sleep studies, and comprehensive care provided by hospital-based sleep centers.
The clinics and retail pharmacies segment fulfills the remaining narcolepsy drug market needs. Clinics offer convenient access to diagnosis and treatment for patients, while retail pharmacies play a vital role in medication distribution and patient education.

Segmentation by Age Group

The pediatric segment is projected to exhibit the highest CAGR. Narcolepsy can affect individuals of all ages, including children and adolescents. Addressing the unique needs of pediatric narcolepsy patients is gaining attention, leading to the development of pediatric-friendly formulations and dosing.
In 2022, adults currently led the market share, with over 65%. Narcolepsy is often diagnosed in adulthood, and the majority of narcolepsy patients fall into this age group. Management of symptoms in adult patients remains a significant focus for pharmaceutical companies.

Segmentation by Region

North America’s robust healthcare infrastructure and research capabilities make it a highly lucrative region, holding over one-third of the global narcolepsy drugs market share in 2022. The presence of leading pharmaceutical companies, research institutions, and specialized sleep clinics contributes to the regional prominence.
Asia Pacific and Europe collectively contribute to nearly 54% of the market share, with the Asia Pacific region displaying key growth potential. Europe’s substantial share of over 20% in the same year reflects its established medical facilities and robust market presence. The Asia Pacific market growth is attributed to increasing awareness, improving healthcare access, and a rising number of diagnosed narcolepsy cases.
The rest of the world, encompassing regions like Latin America, the Middle East, and Africa, contributes to the remaining demand for narcolepsy drugs, offering untapped growth opportunities in emerging markets.

The rising frequency of narcolepsy and the increasing number of obese people across the globe contribute to the market growth of narcolepsy drugs. Narcolepsy affects around three million people globally, according to the Narcolepsy Network, with a substantial proportion of instances documented in the United States, where two out of every 1,500 persons are affected. Narcolepsy is a chronic disease that has a negative impact on a person’s quality of life.

North America dominates the global narcolepsy drugs market. This is due to an increase in the number of people seeking treatment for sleep disorders in Canada and the United States. The rising prevalence of narcolepsy has raised awareness, and higher healthcare spending is expected to fuel the North American market. In addition, favorable reimbursement policies for treatments, a robust clinical pipeline, and increasing stress levels among the regional population are expected to boost market revenue growth. Narcolepsy affects between 135,000 – 200,000 people in the U.S., according to a data sheet published in November 2021 by the National Institute of Neurological Disorders & Stroke. However, the number may be substantially higher as this disorder is commonly misdiagnosed. The higher prevalence of narcolepsy in developed countries such as the U.S. will lead to increasing adoption of narcolepsy treatments, propelling market expansion in this region.

Over the projection period, the Asia Pacific is estimated to be the fastest-growing market for narcolepsy drugs due to increasing awareness of sleep disorders, rising diagnosis rates, expanding healthcare infrastructure, and growing healthcare expenditure in the region. With their vast populations, emerging markets in nations like China and India offer significant development potential. The introduction of telemedicine and digital health technologies in the region is enhancing access to medical treatment, and pharmaceutical firms and research institutes are collaborating and forming partnerships to make it easier to enter the market. Moreover, regulatory support is streamlining drug approvals, contributing to the rapid regional market expansion.

Key Highlights of the Report

The global narcolepsy drugs market is segmented by drug class, symptom management, end-user, age group, and region. Notably, tricyclic antidepressants (TCAs) are poised for substantial growth within the drug class segment, owing to their potential to address cataplexy and enhance nighttime sleep quality in narcolepsy patients. Meanwhile, the cataplexy segment is expected to exhibit the highest growth rate among symptom management categories, focusing on innovative solutions for this challenging narcolepsy symptom. Excessive daytime sleepiness (EDS) dominates the symptom management segment, reflecting the persistent demand for efficacious EDS management. Hospitals play a pivotal role as the dominant end-user category, offering specialized diagnostic services and comprehensive care. At the same time, the pediatric segment is projected to exhibit significant growth, addressing the unique needs of younger narcolepsy patients.

The primary drivers of the swift expansion of the narcolepsy drugs market are the rising prevalence of narcolepsy, higher awareness of sleep disorders as a result of narcolepsy awareness campaigns and camps, and the expanding presence of reimbursement policies. Furthermore, increasing disposable incomes and higher government investments in the healthcare sector, particularly in emerging countries, are likely to benefit the narcolepsy drugs market over the coming years. The main drawbacks that can have a negative impact on the industry’s growth throughout the projected period are the side effects associated with narcolepsy drugs and the potential for delayed or incorrect diagnosis.

North America holds a prominent position in the global narcolepsy drugs market, owing to its robust healthcare infrastructure, extensive research capabilities, and high prevalence of narcolepsy cases. The United States, in particular, plays a major role in propelling market growth due to its advanced healthcare system and increasing awareness of narcolepsy-related issues. On the other hand, the Asia Pacific offers substantial growth potential, driven by improving healthcare access, rising awareness of narcolepsy, and a burgeoning middle-class population. Countries like India, Japan, China, and South Korea are witnessing notable growth in the narcolepsy drugs market, making the Asia Pacific a region with promising opportunities for market expansion.

What Are The Main Drivers Of The Global Narcolepsy Drugs Market?

The main drivers of the global narcolepsy drugs market are the increasing prevalence of narcolepsy worldwide, with a growing number of diagnosed cases, heightened awareness of the condition, and a rising demand for effective treatments. Besides, ongoing pharmaceutical innovations, with the development of novel drug formulations and mechanisms of action, are expanding treatment options and improving patient outcomes. The granting of orphan drug status to many narcolepsy medications incentivizes research & development efforts, further fueling market growth. Moreover, a shift toward patient-centric care, coupled with the emergence of combination therapies and personalized treatment approaches, is enhancing the overall management of narcolepsy, driving the market’s expansion.

What Are The Major Challenges Faced By The Global Narcolepsy Drugs Market?

The major challenges faced by the global narcolepsy drugs market include the complexity of narcolepsy itself, with its diverse range of symptoms and varying severity, making treatment optimization a complex task. Regulatory variations across regions pose limitations to drug approval and market entry. Safety concerns, especially related to the potential for abuse and misuse of stimulant medications, necessitate stringent monitoring and regulations. Moreover, narcolepsy drugs often come with high treatment costs, impacting affordability and accessibility for some patients. Furthermore, the limited availability of specialized sleep clinics and narcolepsy experts in certain regions can hinder early diagnosis and comprehensive care.

What Are The Growth Opportunities In The Global Narcolepsy Drugs Market?

The global narcolepsy drugs market presents growth opportunities driven by several factors, including the continuous expansion of the narcolepsy patient population, heightened awareness campaigns, and a growing demand for improved treatment options. In addition, the emergence of innovative therapies, such as orexin receptor agonists, and the development of patient-centric treatment approaches offer prospects for market developments. Collaboration between pharmaceutical companies and research institutions for the advancement of narcolepsy drug development, along with the exploration of potential narcolepsy drugs for pediatric populations, further expands the market’s horizons. As the healthcare industry increasingly focuses on personalized medicine and telemedicine solutions, these trends can enhance narcolepsy care and contribute to market expansion.

Market Drivers

Several factors drive the global narcolepsy drugs market. The following are the key drivers of the global narcolepsy drugs market:

Increased Prevalence and Diagnosis of Narcolepsy

One of the primary drivers of the global narcolepsy drugs market growth is the growing prevalence of narcolepsy and improved diagnosis rates. Narcolepsy, a chronic sleep disorder, is becoming more recognized and diagnosed worldwide. Factors such as changing lifestyles, rising stress levels, and greater awareness of sleep disorders contribute to the growing prevalence. As more individuals are accurately diagnosed with narcolepsy, there is a higher demand for effective pharmaceutical interventions. According to the report ‘Narcolepsy Presentation in Diverse Populations: an Update,’ released in November 2020, narcolepsy affects 0.87-1.21% of the world’s population, particularly narcolepsy type 1 (NT1). This increasing patient pool provides a major market opportunity for pharmaceutical companies as more individuals seek treatment and management of their narcolepsy symptoms.

Market Restraints

The global narcolepsy drugs market faces challenges that may hinder its growth. These include the following:

Safety Concerns and Potential for Misuse

Narcolepsy drugs, particularly stimulant medications like amphetamines and methylphenidate, have the potential for abuse and misuse due to their stimulating effects. Misuse can lead to addiction, cardiovascular issues, and other health risks. Thus, regulatory agencies impose strict controls on these drugs, including scheduling them as controlled substances. This classification results in tighter monitoring, prescribing restrictions, and patient education requirements, adding complexity to their prescription and use. The concern about misuse and abuse can also lead to hesitancy among healthcare providers to prescribe narcolepsy drugs, particularly to patients with a history of substance abuse. Balancing the need for narcolepsy treatment with the potential risks of misuse presents a challenge for both healthcare providers and pharmaceutical companies in the market.

Opportunities

The global narcolepsy drugs market offers significant growth opportunities. These include the following:

Advancements in Drug Development and Personalized Medicine

Advances in drug development techniques and personalized medicine present a promising opportunity for the narcolepsy drugs market. Pharmaceutical companies are actively investing in R&D to discover and develop innovative narcolepsy medications with improved efficacy and safety profiles. These drugs may target specific narcolepsy symptoms, such as cataplexy or excessive daytime sleepiness, more precisely. Besides, advancements in pharmacogenomics and biomarker research allow for personalized treatment approaches. Tailoring narcolepsy drugs to individual patient profiles can optimize treatment outcomes and minimize side effects. The adoption of personalized medicine not only enhances patient care but also creates a competitive advantage for pharmaceutical companies by offering differentiated and more effective narcolepsy treatments.

Competitive Landscape

Key Players

The competitive landscape of the global narcolepsy drugs market is characterized by several key players, pharmaceutical companies, and research organizations actively engaged in the development and commercialization of narcolepsy medications. The following are some of the top market players and their market shares:

Arena Pharmaceutical Inc
Jazz Pharmaceutical Plc
Bioprojet Pharma Sarl
Ligand Pharmaceuticals Inc
Shinogi Inc
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries Ltd
Harmony Biosciences
Novartis AG
Rhodes Pharmaceuticals L.P.
Others

Established pharmaceutical companies such as Jazz Pharmaceuticals, Takeda Pharmaceutical Company, and Teva Pharmaceuticals are prominent players in the narcolepsy drugs market. These companies have a strong presence in the market and offer a range of narcolepsy medications. These companies are heavily investing in the discovery of new drug candidates, novel formulations, and mechanisms of action to improve narcolepsy treatment efficacy. Market players are also adopting patient-centric approaches, providing educational resources, patient support programs, and telehealth services to enhance treatment adherence and patient outcomes.

In May 2023, Lumryz, a drug developed by Avadel Pharmaceuticals for the treatment of narcolepsy, received final FDA approval in the United States.

In March 2022, the U.S. Food & Drug Administration (FDA) granted Orphan Drug Exclusivity (ODE) to Jazz Pharmaceuticals’ oral medication Xywav (magnesium, potassium, calcium, and sodium oxybates), which was created for the treatment of adult patients with idiopathic hypersomnia.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The increased prevalence of narcoleptic conditions worldwide, escalating stress levels, a rapidly growing geriatric population, and expanding awareness about various treatment choices for this disorder are some of the key factors predicted to drive the narcolepsy drugs market.
Market segmented by drug class, symptom management, end-user, age group, and region.
Stimulants, including amphetamines and methylphenidate-based drug class, currently dominate the market share, primarily used to manage excessive daytime sleepiness (EDS) in narcolepsy patients.
Hospitals account for the largest share of narcolepsy drug demand, offering specialized diagnostic services and comprehensive care.
The market is witnessing a growing focus on narcolepsy treatment in pediatric patients, as early diagnosis and intervention are important for managing the condition effectively in children and adolescents.
Regulatory challenges and the potential for drug misuse remain key restraints in the market, impacting the approval process and prescribing practices.

Future Outlook

Wearable devices, such as actigraphy trackers and smartwatches, are being integrated into narcolepsy care to monitor sleep patterns and aid in treatment optimization.
Emerging advancements in pharmacogenomics and biomarker research will enable personalized treatment approaches for narcolepsy patients, optimizing therapy outcomes and reducing side effects.
The adoption of telemedicine and remote monitoring in narcolepsy care is expected to increase, allowing patients to access specialized care more conveniently and facilitating remote follow-up and medication management.

Segmentation

By Drug Class
- Stimulants
- Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs)
- Tricyclic Antidepressants (TCAs)
- Histamine H3 Receptor Antagonists
By Symptom Management
- Excessive Daytime Sleepiness (EDS)
- Cataplexy
- Sleep Paralysis and Hallucinations
- Overall Symptom Management
By End User
- Hospitals
- Clinics
- Retail Pharmacies
By Age Group
- Pediatric
- Adult
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the narcolepsy drugs market. The key adjacent markets for the narcolepsy drugs market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Narcolepsy Drugs Market

2.1.1. Global Narcolepsy Drugs Market, By Drug Class

2.1.2. Global Narcolepsy Drugs Market, By Symptom Management

2.1.3. Global Narcolepsy Drugs Market, By End User

2.1.4. Global Narcolepsy Drugs Market, By Age Group

2.1.5. Global Narcolepsy Drugs Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Narcolepsy Drugs Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Narcolepsy Drugs Market Drivers

3.2.2. Narcolepsy Drugs Market Restraints

3.2.3. Narcolepsy Drugs Market Opportunities

3.2.4. Major Narcolepsy Drugs Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Drug Class

3.5.2. Symptom Management

3.5.3. End User

3.5.4. Age Group

3.5.5. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Narcolepsy Drugs Market: Company Market Share, Value 2022

4.1.2. Global Narcolepsy Drugs Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Narcolepsy Drugs Market: Top 3 Company Market Share, Value 2022

4.2. Global Narcolepsy Drugs Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Narcolepsy Drugs Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Narcolepsy Drugs Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Narcolepsy Drugs Market, By Drug Class

8.1. Global Narcolepsy Drugs Market Overview, by Drug Class

8.1.1. Global Narcolepsy Drugs Market Revenue Share, By Drug Class, 2022 Vs 2030 (in %)

8.2. Stimulants

8.2.1. Global Narcolepsy Drugs Market, By Stimulants, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Stimulants

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs)

8.3.1. Global Narcolepsy Drugs Market, By Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs), By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs)

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Tricyclic Antidepressants (TCAs)

8.4.1. Global Narcolepsy Drugs Market, By Tricyclic Antidepressants (TCAs), By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Tricyclic Antidepressants (TCAs)

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Histamine H3 Receptor Antagonists

8.5.1. Global Narcolepsy Drugs Market, By Histamine H3 Receptor Antagonists, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Histamine H3 Receptor Antagonists

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

9. Global Narcolepsy Drugs Market, By Symptom Management

9.1. Global Narcolepsy Drugs Market Overview, by Symptom Management

9.1.1. Global Narcolepsy Drugs Market Revenue Share, By Symptom Management, 2022 Vs 2030 (in %)

9.2. Excessive Daytime Sleepiness (EDS)

9.2.1. Global Narcolepsy Drugs Market, By Excessive Daytime Sleepiness (EDS), By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Excessive Daytime Sleepiness (EDS)

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Cataplexy

9.3.1. Global Narcolepsy Drugs Market, By Cataplexy, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Cataplexy

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Sleep Paralysis and Hallucinations

9.4.1. Global Narcolepsy Drugs Market, By Sleep Paralysis and Hallucinations, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Sleep Paralysis and Hallucinations

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Overall Symptom Management

9.5.1. Global Narcolepsy Drugs Market, By Overall Symptom Management, By Region, 2017-2030 (US$ Mn)

9.5.2. Market Dynamics for Overall Symptom Management

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

10. Global Narcolepsy Drugs Market, By End User

10.1. Global Narcolepsy Drugs Market Overview, by End User

10.1.1. Global Narcolepsy Drugs Market Revenue Share, By End User, 2022 Vs 2030 (in %)

10.2. Hospitals

10.2.1. Global Narcolepsy Drugs Market, By Hospitals, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospitals

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Clinics

10.3.1. Global Narcolepsy Drugs Market, By Clinics, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Clinics

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Retail Pharmacies

10.4.1. Global Narcolepsy Drugs Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Retail Pharmacies

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

11. Global Narcolepsy Drugs Market, By Age Group

11.1. Global Narcolepsy Drugs Market Overview, by Age Group

11.1.1. Global Narcolepsy Drugs Market Revenue Share, By Age Group, 2022 Vs 2030 (in %)

11.2. Pediatric

11.2.1. Global Narcolepsy Drugs Market, By Pediatric, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Pediatric

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Adult

11.3.1. Global Narcolepsy Drugs Market, By Adult, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Adult

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

12. Global Narcolepsy Drugs Market, By Region

12.1. Global Narcolepsy Drugs Market Overview, by Region

12.1.1. Global Narcolepsy Drugs Market, By Region, 2022 vs 2030 (in%)

12.2. Drug Class

12.2.1. Global Narcolepsy Drugs Market, By Drug Class, 2017-2030 (US$ Mn)

12.3. Symptom Management

12.3.1. Global Narcolepsy Drugs Market, By Symptom Management, 2017-2030 (US$ Mn)

12.4. End User

12.4.1. Global Narcolepsy Drugs Market, By End User, 2017-2030 (US$ Mn)

12.5. Age Group

12.5.1. Global Narcolepsy Drugs Market, By Age Group, 2017-2030 (US$ Mn)

13. North America Narcolepsy Drugs Market Analysis

13.1. Overview

13.1.1. Market Dynamics for North America

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. North America Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. North America Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. North America Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. North America Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

13.5.1. Overview

13.5.2. SRC Analysis

13.6. North America Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

13.6.1. North America Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

13.6.2. U.S.

13.6.3. Canada

13.6.4. Mexico

14. Europe Narcolepsy Drugs Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Europe Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Europe Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Europe Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Europe Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. Europe Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

14.6.1. Europe Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

14.6.2. UK

14.6.3. France

14.6.4. Germany

14.6.5. Italy

14.6.6. Spain

14.6.7. Benelux

14.6.8. Russia

14.6.9. Rest of Europe

15. Asia Pacific Narcolepsy Drugs Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Asia Pacific Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Asia Pacific Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Asia Pacific Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Asia Pacific Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Asia Pacific Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

15.6.1. Asia Pacific Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

15.6.2. China

15.6.3. Japan

15.6.4. India

15.6.5. South Korea

15.6.6. South East Asia

15.6.7. Rest of Asia Pacific

16. Latin America Narcolepsy Drugs Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Latin America Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Latin America Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Latin America Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Latin America Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Latin America Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

16.6.1. Latin America Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

16.6.2. Brazil

16.6.3. Argentina

16.6.4. Rest of Latin America

17. Middle East Narcolepsy Drugs Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Middle East Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Middle East Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Middle East Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Middle East Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Middle East Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

17.6.1. Middle East Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

17.6.2. UAE

17.6.3. Saudi Arabia

17.6.4. Rest of Middle East

18. Africa Narcolepsy Drugs Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Africa Narcolepsy Drugs Market, by Drug Class, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Africa Narcolepsy Drugs Market, by Symptom Management, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Africa Narcolepsy Drugs Market, by End User, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Africa Narcolepsy Drugs Market, by Age Group, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Africa Narcolepsy Drugs Market, by Country, 2017-2030 (US$ Mn)

18.6.1. Middle East Narcolepsy Drugs Market, by Country, 2022 Vs 2030 (in%)

18.6.2. South Africa

18.6.3. Egypt

18.6.4. Rest of Africa

19. Company Profiles

19.1. Arena Pharmaceutical Inc

19.1.1. Company Overview

19.1.2. Products/Services Portfolio

19.1.3. Geographical Presence

19.1.4. SWOT Analysis

19.1.5. Financial Summary

19.1.5.1. Market Revenue and Net Profit (2019-2022)

19.1.5.2. Business Segment Revenue Analysis

19.1.5.3. Geographical Revenue Analysis

19.2. Jazz Pharmaceutical Plc

19.3. Bioprojet Pharma Sarl

19.4. Ligand Pharmaceuticals Inc

19.5. Shinogi Inc

19.6. Takeda Pharmaceutical Company

19.7. Teva Pharmaceutical Industries Ltd

19.8. Harmony Biosciences

19.9. Novartis AG

19.10. Rhodes Pharmaceuticals L.P.

19.11. Others

20. Research Methodology

20.1. Research Methodology

20.2. Phase I – Secondary Research

20.3. Phase II – Data Modelling

20.3.1. Company Share Analysis Model

20.3.2. Revenue Based Modelling

20.4. Phase III – Primary Research

20.5. Research Limitations

20.5.1. Assumptions

List of Figures

FIG. 1 Global Narcolepsy Drugs Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Narcolepsy Drugs Market Segmentation

FIG. 4 Global Narcolepsy Drugs Market, by Drug Class, 2022 (US$ Mn)

FIG. 5 Global Narcolepsy Drugs Market, by Symptom Management, 2022 (US$ Mn)

FIG. 6 Global Narcolepsy Drugs Market, by End User, 2022 (US$ Mn)

FIG. 7 Global Narcolepsy Drugs Market, by Age Group, 2022 (US$ Mn)

FIG. 8 Global Narcolepsy Drugs Market, by Geography, 2022 (US$ Mn)

FIG. 9 Attractive Investment Proposition, by Drug Class, 2022

FIG. 10 Attractive Investment Proposition, by Symptom Management, 2022

FIG. 11 Attractive Investment Proposition, by End User, 2022

FIG. 12 Attractive Investment Proposition, by Age Group, 2022

FIG. 13 Attractive Investment Proposition, by Geography, 2022

FIG. 14 Global Market Share Analysis of Key Narcolepsy Drugs Market Manufacturers, 2022

FIG. 15 Global Market Positioning of Key Narcolepsy Drugs Market Manufacturers, 2022

FIG. 16 Global Narcolepsy Drugs Market Value Contribution, By Drug Class, 2022 & 2030 (Value %)

FIG. 17 Global Narcolepsy Drugs Market, by Stimulants, Value, 2017-2030 (US$ Mn)

FIG. 18 Global Narcolepsy Drugs Market, by Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs), Value, 2017-2030 (US$ Mn)

FIG. 19 Global Narcolepsy Drugs Market, by Tricyclic Antidepressants (TCAs), Value, 2017-2030 (US$ Mn)

FIG. 20 Global Narcolepsy Drugs Market, by Histamine H3 Receptor Antagonists, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Narcolepsy Drugs Market Value Contribution, By Symptom Management, 2022 & 2030 (Value %)

FIG. 22 Global Narcolepsy Drugs Market, by Excessive Daytime Sleepiness (EDS), Value, 2017-2030 (US$ Mn)

FIG. 23 Global Narcolepsy Drugs Market, by Cataplexy, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Narcolepsy Drugs Market, by Sleep Paralysis and Hallucinations, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Narcolepsy Drugs Market, by Overall Symptom Management, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Narcolepsy Drugs Market Value Contribution, By End User, 2022 & 2030 (Value %)

FIG. 27 Global Narcolepsy Drugs Market, by Hospitals, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Narcolepsy Drugs Market, by Clinics, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Narcolepsy Drugs Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 30 Global Narcolepsy Drugs Market Value Contribution, By Age Group, 2022 & 2030 (Value %)

FIG. 31 Global Narcolepsy Drugs Market, by Pediatric, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Narcolepsy Drugs Market, by Adult, Value, 2017-2030 (US$ Mn)

FIG. 33 North America Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 34 U.S. Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 35 Canada Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 36 Mexico Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 37 Europe Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 38 Germany Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 39 France Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 40 U.K. Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 41 Italy Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 42 Spain Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 43 Benelux Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 44 Russia Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 45 Rest of Europe Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 46 Asia Pacific Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 47 China Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 48 Japan Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 49 India Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 50 South Korea Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 51 South-East Asia Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 52 Rest of Asia Pacific Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 53 Latin America Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 54 Brazil Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 55 Argentina Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 56 Rest of Latin America Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 57 Middle East Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 58 UAE Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 59 Saudi Arabia Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 60 Rest of Middle East Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 61 Africa Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 62 South Africa Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 63 Egypt Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

FIG. 64 Rest of Africa Narcolepsy Drugs Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Narcolepsy Drugs Market

TABLE 2 Global Narcolepsy Drugs Market: Market Drivers Impact Analysis

TABLE 3 Global Narcolepsy Drugs Market: Market Restraints Impact Analysis

TABLE 4 Global Narcolepsy Drugs Market, by Competitive Benchmarking, 2022

TABLE 5 Global Narcolepsy Drugs Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Narcolepsy Drugs Market, by Key Strategies Analysis, 2022

TABLE 7 Global Narcolepsy Drugs Market, by Stimulants, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Narcolepsy Drugs Market, by Stimulants, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Narcolepsy Drugs Market, by Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs), By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Narcolepsy Drugs Market, by Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs), By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Narcolepsy Drugs Market, by Tricyclic Antidepressants (TCAs), By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Narcolepsy Drugs Market, by Tricyclic Antidepressants (TCAs), By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Narcolepsy Drugs Market, by Histamine H3 Receptor Antagonists, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Narcolepsy Drugs Market, by Histamine H3 Receptor Antagonists, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Narcolepsy Drugs Market, by Excessive Daytime Sleepiness (EDS), By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Narcolepsy Drugs Market, by Excessive Daytime Sleepiness (EDS), By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Narcolepsy Drugs Market, by Cataplexy, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Narcolepsy Drugs Market, by Cataplexy, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Narcolepsy Drugs Market, by Sleep Paralysis and Hallucinations, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Narcolepsy Drugs Market, by Sleep Paralysis and Hallucinations, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Narcolepsy Drugs Market, by Overall Symptom Management, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Narcolepsy Drugs Market, by Overall Symptom Management, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Narcolepsy Drugs Market, by Hospitals, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Narcolepsy Drugs Market, by Hospitals, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Narcolepsy Drugs Market, by Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Narcolepsy Drugs Market, by Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Narcolepsy Drugs Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Narcolepsy Drugs Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Narcolepsy Drugs Market, by Pediatric, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Narcolepsy Drugs Market, by Pediatric, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Narcolepsy Drugs Market, by Adult, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Narcolepsy Drugs Market, by Adult, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 34 Global Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 35 Global Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 36 Global Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 37 Global Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 38 Global Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 39 Global Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 40 Global Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 41 Global Narcolepsy Drugs Market, by Region, 2017-2022 (US$ Mn)

TABLE 42 Global Narcolepsy Drugs Market, by Region, 2023-2030 (US$ Mn)

TABLE 43 North America Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 44 North America Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 45 North America Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 46 North America Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 47 North America Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 48 North America Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 49 North America Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 50 North America Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 51 North America Narcolepsy Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 52 North America Narcolepsy Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 53 United States Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 54 United States Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 55 United States Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 56 United States Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 57 United States Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 58 United States Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 59 United States Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 60 United States Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 61 Canada Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 62 Canada Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 63 Canada Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 64 Canada Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 65 Canada Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 66 Canada Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 67 Canada Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 68 Canada Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 69 Mexico Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 70 Mexico Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 71 Mexico Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 72 Mexico Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 73 Mexico Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 74 Mexico Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 75 Mexico Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 76 Mexico Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 77 Europe Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 78 Europe Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 79 Europe Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 80 Europe Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 81 Europe Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 82 Europe Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 83 Europe Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 84 Europe Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 85 Europe Narcolepsy Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 86 Europe Narcolepsy Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 87 Germany Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 88 Germany Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 89 Germany Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 90 Germany Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 91 Germany Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 92 Germany Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 93 Germany Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 94 Germany Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 95 France Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 96 France Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 97 France Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 98 France Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 99 France Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 100 France Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 101 France Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 102 France Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 103 United Kingdom Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 104 United Kingdom Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 105 United Kingdom Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 106 United Kingdom Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 107 United Kingdom Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 108 United Kingdom Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 109 United Kingdom Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 110 United Kingdom Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 111 Italy Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 112 Italy Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 113 Italy Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 114 Italy Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 115 Italy Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 116 Italy Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 117 Italy Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 118 Italy Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 119 Spain Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 120 Spain Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 121 Spain Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 122 Spain Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 123 Spain Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 124 Spain Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 125 Spain Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 126 Spain Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 127 Benelux Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 128 Benelux Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 129 Benelux Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 130 Benelux Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 131 Benelux Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 132 Benelux Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 133 Benelux Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 134 Benelux Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 135 Russia Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 136 Russia Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 137 Russia Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 138 Russia Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 139 Russia Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 140 Russia Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 141 Russia Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 142 Russia Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 143 Rest of Europe Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 144 Rest of Europe Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 145 Rest of Europe Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 146 Rest of Europe Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 147 Rest of Europe Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 148 Rest of Europe Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 149 Rest of Europe Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 150 Rest of Europe Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 151 Asia Pacific Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 152 Asia Pacific Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 153 Asia Pacific Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 154 Asia Pacific Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 155 Asia Pacific Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 156 Asia Pacific Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 157 Asia Pacific Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 158 Asia Pacific Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 159 China Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 160 China Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 161 China Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 162 China Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 163 China Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 164 China Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 165 China Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 166 China Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 167 Japan Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 168 Japan Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 169 Japan Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 170 Japan Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 171 Japan Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 172 Japan Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 173 Japan Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 174 Japan Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 175 India Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 176 India Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 177 India Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 178 India Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 179 India Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 180 India Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 181 India Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 182 India Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 183 South Korea Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 184 South Korea Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 185 South Korea Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 186 South Korea Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 187 South Korea Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 188 South Korea Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 189 South Korea Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 190 South Korea Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 191 South-East Asia Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 192 South-East Asia Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 193 South-East Asia Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 194 South-East Asia Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 195 South-East Asia Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 196 South-East Asia Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 197 South-East Asia Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 198 South-East Asia Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 199 Rest of Asia Pacific Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 200 Rest of Asia Pacific Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 201 Rest of Asia Pacific Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 202 Rest of Asia Pacific Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 203 Rest of Asia Pacific Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 204 Rest of Asia Pacific Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 205 Rest of Asia Pacific Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 206 Rest of Asia Pacific Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 207 Latin America Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 208 Latin America Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 209 Latin America Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 210 Latin America Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 211 Latin America Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 212 Latin America Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 213 Latin America Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 214 Latin America Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 215 Brazil Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 216 Brazil Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 217 Brazil Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 218 Brazil Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 219 Brazil Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 220 Brazil Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 221 Brazil Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 222 Brazil Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 223 Argentina Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 224 Argentina Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 225 Argentina Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 226 Argentina Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 227 Argentina Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 228 Argentina Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 229 Argentina Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 230 Argentina Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 231 Rest of Latin America Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 232 Rest of Latin America Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 233 Rest of Latin America Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 234 Rest of Latin America Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 235 Rest of Latin America Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 236 Rest of Latin America Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 237 Rest of Latin America Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 238 Rest of Latin America Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 239 Middle East Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 240 Middle East Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 241 Middle East Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 242 Middle East Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 243 Middle East Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 244 Middle East Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 245 Middle East Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 246 Middle East Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 247 UAE Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 248 UAE Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 249 UAE Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 250 UAE Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 251 UAE Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 252 UAE Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 253 UAE Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 254 UAE Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 255 Saudi Arabia Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 256 Saudi Arabia Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 257 Saudi Arabia Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 258 Saudi Arabia Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 259 Saudi Arabia Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 260 Saudi Arabia Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 261 Saudi Arabia Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 262 Saudi Arabia Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 263 Rest of Middle East Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 264 Rest of Middle East Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 265 Rest of Middle East Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 266 Rest of Middle East Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 267 Rest of Middle East Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 268 Rest of Middle East Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 269 Rest of Middle East Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 270 Rest of Middle East Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 271 Africa Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 272 Africa Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 273 Africa Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 274 Africa Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 275 Africa Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 276 Africa Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 277 Africa Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 278 Africa Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 279 South Africa Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 280 South Africa Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 281 South Africa Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 282 South Africa Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 283 South Africa Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 284 South Africa Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 285 South Africa Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 286 South Africa Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 287 Egypt Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 288 Egypt Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 289 Egypt Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 290 Egypt Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 291 Egypt Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 292 Egypt Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 293 Egypt Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 294 Egypt Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 295 Rest of Africa Narcolepsy Drugs Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 296 Rest of Africa Narcolepsy Drugs Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 297 Rest of Africa Narcolepsy Drugs Market, by Symptom Management, 2017-2022 (US$ Mn)

TABLE 298 Rest of Africa Narcolepsy Drugs Market, by Symptom Management, 2023-2030 (US$ Mn)

TABLE 299 Rest of Africa Narcolepsy Drugs Market, by End User, 2017-2022 (US$ Mn)

TABLE 300 Rest of Africa Narcolepsy Drugs Market, by End User, 2023-2030 (US$ Mn)

TABLE 301 Rest of Africa Narcolepsy Drugs Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 302 Rest of Africa Narcolepsy Drugs Market, by Age Group, 2023-2030 (US$ Mn)

Frequently asked questions

What is the current size of the global narcolepsy drugs market?

The global narcolepsy drugs market was valued at USD 2748.5 Million in 2022.

What is the expected growth rate of the narcolepsy drugs market between 2023 and 2030?

The narcolepsy drugs market is expected to grow at a CAGR of 9.9% between 2023 and 2030, reaching USD 5848.9 Million in 2030.

Which segment is leading the market share in terms of drug class?

Stimulants are the leading segment by drug class, holding over 30% share in value in 2022.

Which symptom management segment governs the global demand for narcolepsy drugs?

The excessive daytime sleepiness (EDS) segment governs the global demand for narcolepsy drugs, holding a massive market share of over 35% in 2022.

Which end-user segment will post the highest CAGR in the forecast period?

The clinics segment will post the highest CAGR in the projection period.

Which region is fueling the growth of the narcolepsy drugs industry?

North America is driving the rapid growth of the narcolepsy drugs industry, accounting for more than one-third of its market share in 2022.

Who are the major players in the global narcolepsy drugs market?

The top players include Arena Pharmaceutical Inc, Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Inc, Shinogi Inc, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Harmony Biosciences, Novartis AG, Rhodes Pharmaceuticals L.P., and Others.

What are the major market drivers of the narcolepsy drugs industry?

The major market drivers of the narcolepsy drugs industry include increasing prevalence and diagnosis rates of narcolepsy, ongoing research and development efforts, rising awareness of sleep disorders, and regulatory incentives for orphan drug status.

What are the major market restraints of the narcolepsy drugs industry?

The major market restraints of the narcolepsy drugs industry include complex and lengthy regulatory approval processes, safety concerns regarding the potential for drug misuse, high development costs, and the challenges of balancing treatment needs with potential risks.

What are the major market opportunities of the narcolepsy drugs industry?

The major market opportunities in the narcolepsy drugs industry include expanding into emerging markets with growing healthcare access, tapping into previously underserved patient populations, and leveraging advancements in drug development and personalized medicine to provide more effective and tailored treatments for narcolepsy.

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –